Biotech / Pharma
Crystalys Therapeutics
Biotech / Pharma
Crystalys Therapeutics, a San Diego biotech startup developing dotinurad (an oral second-line gout therapy), raised $130 million in Series B led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, and others.
Founded
Region
Investors
- Frazier Life Sciences
- Wellington Management
- HBM Healthcare Investments
- Soleus Capital
- Cormorant Asset Management
- Trails Edge Capital Partners
- Pivotal bioVenture Partners
- KCap Biotechnology Fund
- Novo Holdings
- SR One
- Catalys Pacific
- Perceptive Xontogeny Venture Funds
- Lightstone Ventures
- AN Venture Partners
- abrdn
- Pontifax
- Longwood Fund
- Alexandria Venture Investments
- Wedbush Healthcare Partners
- Prebys Ventures
People